Cell Signaling Technology

Product Pathways - Ca / cAMP / Lipid Signaling

SignalSilence® PKA C-α siRNA Kit #6575

Products Included No. Quantity Isotype Assay
SignalSilence® PKA C-α siRNA I 6406 10 µM in 150 µl 50 Transfections
SignalSilence® PKA C-α siRNA II 6574 10 µM in 150 µl 50 Transfections
PKA C-α Antibody 4782 40 µl Rabbit IgG 4 Western mini blots

Western Blotting

Western Blotting

Western blot analysis of extracts from HeLa cells, transfected with 100 nM SignalSilence® Control siRNA (Fluorescein Conjugate) #6201 (-), SignalSilence® PKA C-α siRNA II (+) or SignalSilence® PKA C-α siRNA I (+), using PKA C-α Antibody and α-Tubulin (11H10) Rabbit mAb #2125. The PKA C-α antibody confirms silencing of PKA C-α expression while α-Tubulin (11H10) Rabbit mAb is used to control for loading and specificity of PKA C-α siRNA.

Description

SignalSilence® PKA C-α siRNA Kit from Cell Signaling Technology (CST) allow the researcher to specifically inhibit PKA C-α expression. The kit utilizes RNA interference, a method whereby gene expression can be selectively silenced through the delivery of double stranded RNA molecules into the cell. All SignalSilence® siRNA products are rigorously tested in-house and have been shown to reduce target protein expression. SignalSilence® PKA C-α siRNA Kit includes PKA C-α siRNA I and II and a target-specific PKA C-α antibody to confirm the silencing of PKA C-α expression by western analysis.

Directions for Use

CST recommends transfection with 100 nM PKA C-α siRNA 48 to 72 hours prior to cell lysis. For transfection procedure, follow protocol provided by the transfection reagent manufacturer. Please feel free to contact CST with any questions on use.

Background

The second messenger cyclic AMP (cAMP) activates cAMP-dependent protein kinase (PKA or cAPK) in mammalian cells and controls many cellular mechanisms such as gene transcription, ion transport and protein phosphorylation (1). Inactive PKA is a heterotetramer composed of a regulatory subunit (R) dimer and a catalytic subunit (C) dimer. In this inactive state, the pseudosubstrate sequences on the R subunits block the active sites on the C subunits. Three C subunit isoforms (C-α, C-β and C-γ) and two families of regulatory subunits (RI and RII) with distinct cAMP binding properties have been identified. The two R families exist in two isoforms, α and β (RI-α, RI-β, RII-α and RII-β). Upon binding of cAMP to the R subunits, the autoinhibitory contact is eased and active monomeric C subunits are released. PKA shares substrate specificity with Akt (PKB) and PKC, which is characterized by an arginine at position -3 relative to the phosphorylated serine or threonine residue (2). Substrates that present this consensus sequence and have been shown to be phosphorylated by PKA are Bad (Ser155), CREB (Ser133) and GSK-3 (GSK-3α Ser21 and GSK-3β Ser9) (3-5). In addition, combined knock-down of PKA C-α and -β blocks cAMP-mediated phosphorylation of Raf (Ser43 and Ser259) (6). Autophosphorylation and phosphorylation by PDK-1 are two known mechanisms responsible for phosphorylation of the C subunit at Thr197 (7).

  1. Montminy, M. (1997) Annu. Rev. Biochem. 66, 807-822.
  2. Dell'Acqua, M.L. and Scott, J.D. (1997) J. Biol. Chem. 272, 12881-12884.
  3. Tan, Y. et al. (2000) J. Biol. Chem. 275, 25865-25869.
  4. Gonzalez, G.A. and Montminy, M.R. (1989) Cell 59, 675-680.
  5. Fang, X. et al. (2000) Proc. Natl. Acad. Sci. USA 97, 11960-11965.
  6. Dumaz, N. and Marais, R. (2003) J. Biol. Chem. 278, 29819 -29823.
  7. Moore, M.J. et al. (2002) J. Biol. Chem. 277, 47878-47884.

Application References

Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!

Protocols

Companion Products

Limited Use Label License, RNA interference: This product is licensed under European Patent 1144623 and foreign equivalents from Ribopharma AG, Kulmbach, Germany and is provided only for use in non-commercial research specifically excluding use (a) in drug discovery or drug development, including target identification or target validation, by or on behalf of a commercial entity, (b) for contract research or commercial screening services, (c) for the production or manufacture of siRNA-related products for sale, or (d) for the generation of commercial databases for sale to Third Parties. Information about licenses for these and other commercial uses is available from Ribopharma AG, Fritz-Hornschuch-Str. 9, D-95326 Kulmbach, Germany.

This product is intended for research purposes only. The product is not intended to be used for therapeutic or diagnostic purposes in humans or animals.

Products